Clinical Prognostic Factors in Patients with Locally Advanced (Stage III) Non-small Cell Lung Cancer Treated with Concurrent Hyperfractionated Radiation Therapy and Chemotherapy

Abstract

Influence of various potential clinical prognostic factors on overall survival (OS), local progression-free survival (LPFS) and the distant metastasis-free survival (DMFS) in patients with locally advanced (stage III) treated with hyperfractionated radiation therapy (Hfx RT) with or without concurrent chemotherapy (CHT) nonsmall cell lung cancer was investigated.